The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Nevro Corp. P/E ratio is -12.26. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Nevro Corp.’s P/E ratio
What is Nevro Corp. P/E Ratio?
The P/E ratio of Nevro Corp. is -12.26, which represents a 81.65% increase over the same period last year. their 1-year average P / E ratio is -28.27 and their 5-year average is -54.06.
What is Nevro Corp. Net EPS?
Nevro Corp.’s net earnings for the most recent quarter were -3.88$, which represents a 96.95% decrease from the same period last year.
Who are Nevro Corp. Competitors?
Based on Jika.io AI model, BioLife Solutions, ClearPoint Neuro, Inogen, Pulmonx, Outset Medical, SmileDirectClub, SI-BONE, ViewRay are considered to be Nevro Corp.’s competitors because the companies operate in the same industry as Nevro Corp. and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Nevro Corp.
Who is Nevro Corp.’s Biggest competitor?
Nevro Corp.’s biggest competitor is BioLife Solutions, based on the Jika.io AI model. it has a similar market capitalization to Nevro Corp. within the industry, it dominates a similar portion of the market share as Nevro Corp., and it provides and markets very similar services.
What industry is Nevro Corp. in?
Nevro Corp. is part of the Medical Devices and Healthcare industry.
Nevro Corp. vs BioLife Solutions
Market Cap: Nevro Corp.’s Market Cap of 1678409216 is higher than BioLife Solutions Market Cap of 690854080.
Average Volume: Nevro Corp.’s Average Volume of 552733.0 is higher than BioLife Solutions Average Volume of 504541.0.
Beta: Nevro Corp.’s Beta of 1.09 is lower than BioLife Solutions Beta of 1.99.
Revenue: Nevro Corp.’s Revenue of 386.905M is higher than BioLife Solutions Revenue of 119.156M.
Net Income: Nevro Corp.’s Net Income of -131.36M is lower than BioLife Solutions Net Income of -48.995M.
Gross Profit: Nevro Corp.’s Gross Profit of 266.042M is lower than BioLife Solutions Gross Profit of 37.748M.
Ebitda: Nevro Corp.’s Ebitda of -102.399M is lower than BioLife Solutions Ebitda of -16.256M.
P/E Ratio: Nevro Corp.’s P/E Ratio of -12.26 is lower than BioLife Solutions P/E Ratio of -34.46.
P/S Ratio: Nevro Corp.’s P/S Ratio of 4.32 is lower than BioLife Solutions P/S Ratio of 4.94.
P/B Ratio: Nevro Corp.’s P/B Ratio of 6.95 is higher than BioLife Solutions P/B Ratio of 1.43.
P/FCF Ratio: Nevro Corp.’s P/FCF Ratio of -22.31 is lower than BioLife Solutions P/FCF Ratio of -50.16.
ROE: Nevro Corp.’s ROE of -0.45 is higher than BioLife Solutions ROE of -0.04.
ROA: Nevro Corp.’s ROA of -0.26 is higher than BioLife Solutions ROA of -0.04.
Return On Capital Employed: Nevro Corp.’s Return On Capital Employed of -0.26 is higher than BioLife Solutions Return On Capital Employed of -0.08.
Gross Profit Margin: Nevro Corp.’s Gross Profit Margin of 0.68 is higher than BioLife Solutions Gross Profit Margin of 0.29.
Assets (Total): Nevro Corp.’s Assets (Total) of 574.544M is higher than BioLife Solutions Assets (Total) of 552.604M.
Debt (Total): Nevro Corp.’s Debt (Total) of 166.712M is lower than BioLife Solutions Debt (Total) of 26.879M.
Nevro Corp. vs ClearPoint Neuro
Market Cap: Nevro Corp.’s Market Cap of 1678409216 is higher than ClearPoint Neuro Market Cap of 328958944.
Average Volume: Nevro Corp.’s Average Volume of 552733.0 is higher than ClearPoint Neuro Average Volume of 238246.0.
Beta: Nevro Corp.’s Beta of 1.09 is lower than ClearPoint Neuro Beta of 1.25.
Revenue: Nevro Corp.’s Revenue of 386.905M is higher than ClearPoint Neuro Revenue of 16.299M.
Net Income: Nevro Corp.’s Net Income of -131.36M is lower than ClearPoint Neuro Net Income of -14.41M.
Gross Profit: Nevro Corp.’s Gross Profit of 266.042M is higher than ClearPoint Neuro Gross Profit of 11.291M.
Ebitda: Nevro Corp.’s Ebitda of -102.399M is lower than ClearPoint Neuro Ebitda of -14.691M.
P/E Ratio: Nevro Corp.’s P/E Ratio of -12.26 is lower than ClearPoint Neuro P/E Ratio of -20.75.
P/S Ratio: Nevro Corp.’s P/S Ratio of 4.32 is higher than ClearPoint Neuro P/S Ratio of 35.27.
P/B Ratio: Nevro Corp.’s P/B Ratio of 6.95 is lower than ClearPoint Neuro P/B Ratio of 7.18.
P/FCF Ratio: Nevro Corp.’s P/FCF Ratio of -22.31 is lower than ClearPoint Neuro P/FCF Ratio of -28.42.
ROE: Nevro Corp.’s ROE of -0.45 is higher than ClearPoint Neuro ROE of -0.34.
ROA: Nevro Corp.’s ROA of -0.26 is lower than ClearPoint Neuro ROA of -0.26.
Return On Capital Employed: Nevro Corp.’s Return On Capital Employed of -0.26 is lower than ClearPoint Neuro Return On Capital Employed of -0.26.
Gross Profit Margin: Nevro Corp.’s Gross Profit Margin of 0.68 is higher than ClearPoint Neuro Gross Profit Margin of 0.42.
Assets (Total): Nevro Corp.’s Assets (Total) of 574.544M is lower than ClearPoint Neuro Assets (Total) of 65.581M.
Debt (Total): Nevro Corp.’s Debt (Total) of 166.712M is higher than ClearPoint Neuro Debt (Total) of 13.298M.
Nevro Corp. vs Inogen
Market Cap: Nevro Corp.’s Market Cap of 1678409216 is higher than Inogen Market Cap of 612227776.
Average Volume: Nevro Corp.’s Average Volume of 552733.0 is higher than Inogen Average Volume of 192146.0.
Beta: Nevro Corp.’s Beta of 1.09 is higher than Inogen Beta of 1.0.
Revenue: Nevro Corp.’s Revenue of 386.905M is higher than Inogen Revenue of 358.003M.
Net Income: Nevro Corp.’s Net Income of -131.36M is lower than Inogen Net Income of -6.333M.
Gross Profit: Nevro Corp.’s Gross Profit of 266.042M is higher than Inogen Gross Profit of 176.483M.
Ebitda: Nevro Corp.’s Ebitda of -102.399M is lower than Inogen Ebitda of 30.287M.
P/E Ratio: Nevro Corp.’s P/E Ratio of -12.26 is lower than Inogen P/E Ratio of -30.79.
P/S Ratio: Nevro Corp.’s P/S Ratio of 4.32 is higher than Inogen P/S Ratio of 1.74.
P/B Ratio: Nevro Corp.’s P/B Ratio of 6.95 is higher than Inogen P/B Ratio of 1.7.
P/FCF Ratio: Nevro Corp.’s P/FCF Ratio of -22.31 is lower than Inogen P/FCF Ratio of -29.98.
ROE: Nevro Corp.’s ROE of -0.45 is higher than Inogen ROE of -0.05.
ROA: Nevro Corp.’s ROA of -0.26 is higher than Inogen ROA of -0.04.
Return On Capital Employed: Nevro Corp.’s Return On Capital Employed of -0.26 is higher than Inogen Return On Capital Employed of -0.01.
Gross Profit Margin: Nevro Corp.’s Gross Profit Margin of 0.68 is higher than Inogen Gross Profit Margin of 0.49.
Assets (Total): Nevro Corp.’s Assets (Total) of 574.544M is higher than Inogen Assets (Total) of 489.513M.
Debt (Total): Nevro Corp.’s Debt (Total) of 166.712M is lower than Inogen Debt (Total) of 26.674M.
Shareholders Equity: Nevro Corp.’s Shareholders Equity of 303.616M is lower than Inogen Shareholders Equity of 370.227M.
Nevro Corp. vs Pulmonx
Market Cap: Nevro Corp.’s Market Cap of 1678409216 is higher than Pulmonx Market Cap of 538190720.
Average Volume: Nevro Corp.’s Average Volume of 552733.0 is lower than Pulmonx Average Volume of 565212.0.
Beta: Nevro Corp.’s Beta of 1.09 is higher than Pulmonx Beta of 0.0.
Revenue: Nevro Corp.’s Revenue of 386.905M is lower than Pulmonx Revenue of 48.416M.
Net Income: Nevro Corp.’s Net Income of -131.36M is lower than Pulmonx Net Income of -48.661M.
Gross Profit: Nevro Corp.’s Gross Profit of 266.042M is lower than Pulmonx Gross Profit of 35.63M.
Ebitda: Nevro Corp.’s Ebitda of -102.399M is lower than Pulmonx Ebitda of -46.622M.
P/E Ratio: Nevro Corp.’s P/E Ratio of -12.26 is higher than Pulmonx P/E Ratio of -10.38.
P/S Ratio: Nevro Corp.’s P/S Ratio of 4.32 is higher than Pulmonx P/S Ratio of 10.68.
P/B Ratio: Nevro Corp.’s P/B Ratio of 6.95 is higher than Pulmonx P/B Ratio of 2.93.
P/FCF Ratio: Nevro Corp.’s P/FCF Ratio of -22.31 is higher than Pulmonx P/FCF Ratio of -10.52.
ROE: Nevro Corp.’s ROE of -0.45 is higher than Pulmonx ROE of -0.26.
ROA: Nevro Corp.’s ROA of -0.26 is higher than Pulmonx ROA of -0.23.
Return On Capital Employed: Nevro Corp.’s Return On Capital Employed of -0.26 is higher than Pulmonx Return On Capital Employed of -0.24.
Gross Profit Margin: Nevro Corp.’s Gross Profit Margin of 0.68 is lower than Pulmonx Gross Profit Margin of 0.74.
Assets (Total): Nevro Corp.’s Assets (Total) of 574.544M is higher than Pulmonx Assets (Total) of 235.173M.
Debt (Total): Nevro Corp.’s Debt (Total) of 166.712M is lower than Pulmonx Debt (Total) of 26.46M.
Shareholders Equity: Nevro Corp.’s Shareholders Equity of 303.616M is higher than Pulmonx Shareholders Equity of 193.239M.
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. the company develops and commercializes Senza’s spinal cord stimulation system, an evidence-based neuromodulation platform for chronic pain, as well as Senza II and Senza Omnia systems. it also provides 10 kHz therapy, which provides neuromodulation solutions for chronic pain based on available clinical evidence. the company sells its products through its direct sales force and through its network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and has its headquarters in Redwood City, California.
